Navigation Links
Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis

tients who reported complete resolution of one cardinal symptom there was an average improvement in endoscopy scores of 12%. In patients who reported resolution of both cardinal symptoms there was an average improvement in endoscopy scores of 23%."

The clinical trial has reached approximately 80% enrollment and the Company believes it will finish enrollment of the 300 patients required for randomization during the summer. Unblinded top-line results for all patients are expected to be available before the end of the year.

Members of the investment community, the media, and other interested parties can access the PowerPoint presentation and an audio webcast by visiting Accentia's homepage at www.accentia.net, or for audio only, http://www.wsw.com/webcast/jeff18/abpi. The PowerPoint presentation and audio will be available and archived on Accentia's website for 90 days.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company" or "Accentia") is a vertically integrated biopharmaceutical company focused on the development and commercialization of drug candidates that are in late-stage clinical development and typically are based on active pharmaceutical ingredients that have been previously approved by the FDA for other indications. Usually these drug candidates can access the accelerated 505(b)(2) regulatory approval pathway, which is generally less time-consuming and less expensive than the typical 505(b)(1) pathway that must be used for new chemical entities. The Company's lead product candidate is SinuNase(TM), a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis. SinuNase has been granted Fast Track status by the FDA and it is currently in a pivotal Phase 3 clinical trial. During this fiscal year, the Company also plans to file an Investigative New Drug (IND) for a pivotal Phase 3 clinical trial of Revimmune, to treat nume
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:11/21/2014)... N.Y. , Nov. 21, 2014  Cardinal Health, ... world,s largest health care services companies, and Henry Schein, ... provider of health care products and services to office-based ... the companies have entered into a long-term strategic agreement ... product offerings to office-based medical practices.  This strategic agreement ...
(Date:11/21/2014)... N.J. , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Krakauer , Chief Executive Officer, will be presenting at the ... New York Palace Hotel in New York ... 2014 at 2:00 PM ET. In addition, Mr. Krakauer and ... available for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... Nov. 20, 2014  The acceptance of two ... AAGL Global Congress demonstrates continued interest in the ... provide bowel control. One of the abstracts, presented by ... Division Chief of Urogynecology and Reconstructive Pelvic Surgery ... Award for Best Written Abstract on Urogynecology/Pelvic Floor ...
Breaking Medicine Technology:Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3
... British Columbia--(BUSINESS WIRE)--Apr 3, 2007 - ... Company(TM),announced today the publication of new ... showing that Allon's product,candidate AL-108 significantly ... the hyperphosphorylation of tau protein in ...
... BASEL, Switzerland, April 3, 2007 (PRIME NEWSWIRE) ... microbiological and,pharmacokinetic profiles of Basilea's (SWX:BSLN) two ... for ceftobiprole, the first anti-MRSA broad-spectrum,cephalosporin in ... for the treatment of invasive fungal infections,yielded ...
Cached Medicine Technology:Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference 2Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 2Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 4Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 5Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 6Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 7
(Date:11/22/2014)... New York, NY (PRWEB) November 22, 2014 ... Australia’s Therapeutics Goods Administration (TGA) approved it for ... Glutathione was approved and listed within the Therapeutic ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione ... Chem, a biotech specialist that sources and imports ...
(Date:11/22/2014)... PITTSBURGH, PA (PRWEB) November 22, 2014 ... about the pain caused by the machine," said an ... injury, she had to go back a second time ... my invention idea." , She developed the patent-pending MAMO ... for breast cancer. The design saves the patient from ...
(Date:11/22/2014)... Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that ... developed Type 2 diabetes due to its use continue ... underway in U.S. District Court, District of South Carolina, ... litigation will convene its next Status Conference on December ... Counsel for Plaintiffs and Defendants to meet and confer, ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 The Sports ... Roy Baroff to its team of conflict resolution ... soccer player, coach, and referee. He has over 30 years ... and beyond. , “I'm very excited to connect with SCI ... sports related interests to a program with a complete sports ...
(Date:11/22/2014)... 2014 Wright & Schulte LLC reports ... have been scheduled between October 2016 and April ... Illinois. U.S. District Judge Matthew F. Kennelly, who is ... Order (CMO) on November 6, 2014 that outlined the ... submit documents and other activities in preparation for the ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
... using small impulses of electricity. This innovative device is ... // (TENS) technology, which has long been used by ... pain. ,The device comes in the form of a ... in the air from the snoring sound. ,Sensors ...
... scientists have developed a test that can detect the Hepatitis ... by Arieh Yaari of Soroka University Medical Centre // ... people without kidney functions whose blood must be passed through ... SciDev Net. ,Such patients have a high incidence of ...
... British Cardiac Society, the British Hypertension Society, Diabetes ... // and the Stroke Association have collaboratively ... attacks, stroke and hardening of leg arteries. The ... of developing heart attacks by properly maintaining one’s ...
... cannot be cured by taking medications reports a study ... review of eight // clinical trials that complementary and ... occur after alcohol consumption. Some of the common hangover ... diarrhea, dizziness, fatigue, depressed, poor memory. ,Though, ...
... Health experts in the United States fear that if the deadly ... risk since they are vulnerable // to the H5N1 virus. ... 70 lives in Asia and has appeared in parts of Europe ... slaughtered in an effort to contain the virus. However, experts fear ...
... study conducted at Oregon Health & Science University and ... that a perfect molecular mixture present in male-emitted pheromone ... and increased aggression) dictates the sexual behavior of other ... interest. ,The researchers argue that release of ...
Cached Medicine News:Health News:The Chemistry Of Sexual Attraction Between Male And Female Elephants 2
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
Medicine Products: